Ornidazole: a new antiprotozoal compound for treatment of Trichomonas vaginalis infection.
A new anti-protozoal compound, ornidazole, a derivative of nitroimidazole, was given in a single 2 g dose to 20 women with Trichomonas vaginalis infection. All the women were cured, but they suffered some side-effects. Plasma levels of ornidazole reached a peak five to eight times higher than minimum inhibitory concentrations and exceeded this level for at least 36 hours. It is therefore possible that a smaller dose might have had an adequate trichomonicidal effect and fewer side-effects. Further studies are in progress.
D000293:Adolescent; D000328:Adult; D000994:Antitrichomonal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008826:Microbial Sensitivity Tests; D009593:Nitroimidazoles / Q000627:therapeutic use*; D009950:Ornidazole / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D014247:Trichomonas Vaginitis / Q000188:drug therapy*
D000994:Antitrichomonal Agents; D009593:Nitroimidazoles; D009950:Ornidazole